3 Global Generics and Specialty Franchise, Branded and Generic Leader and Active Ingredient Manufacturer Stocks With a Strong Future Roadmap: Lupin, Dr. Reddy’s Laboratories and Granules India
- October 23, 2026
- Posted by: Ankit Jaiswal
- Category: Best Stocks
Lupin, Dr. Reddy’s Laboratories and Granules India: ROE of 11.1% to 23.8% and FY22 to FY26 revenue CAGR of 9.2% to 15.0%. Prices as of 22 Oct 2026.
Quick Answer
The three complex generics and active ingredient stocks to watch are Lupin, Dr. Reddy’s Laboratories and Granules India. Their return on equity ranges from 11.1% to 23.8%, and their revenue compound annual growth from FY22 to FY26 ranges from 9.2% to 15.0%. Lupin leads on both return on equity at 23.8% and revenue growth at 15.0% a year. Prices are based on the 22 October 2026 close, and this article is educational, not investment advice.
Complex generics and active ingredient stocks let investors follow companies that make and supply medicines at global scale. Lupin, Dr. Reddy’s Laboratories and Granules India cover a global generics and specialty franchise, a leading generics and branded player and a manufacturer of active ingredients and finished dosages.
This list covers three complex generics and active ingredient stocks with complete current figures: Lupin, Dr. Reddy’s Laboratories and Granules India. Every figure comes from the latest reported financials and the 22 October 2026 market close. Companies without complete current figures were left out.
Click Here – Get Free Investment Predictions
What Are Complex Generics and Active Ingredient Stocks?
Complex generics and active ingredient stocks are listed pharmaceutical companies that make generic formulations and the ingredients behind them. Their earnings depend on approvals, launches and plant capacity.
Complex Generics and Active Ingredient Stocks at a Glance
| Company | CMP (Rs) | Market Cap (Rs Cr) | P/E | Industry P/E | ROE (%) | D/E |
|---|---|---|---|---|---|---|
| Lupin | 1,922 | 89,343 | 16.1 | 36.0 | 23.8 | 0.29 |
| Dr. Reddy’s Laboratories | 1,239 | 103,667 | 32.6 | 36.0 | 11.1 | 0.20 |
| Granules India | 817 | 22,002 | 33.2 | 36.0 | 11.7 | 0.30 |
On valuation, all three trade at a P/E below their industry P/E, which means the market is pricing them at a lower multiple than their peer group. Readers comparing complex generics and active ingredient stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain.
Why Do Complex Generics and Active Ingredient Stocks Have a Strong Roadmap in India?
Complex generics and active ingredient stocks have a strong roadmap in India because global demand for affordable medicines keeps growing, and Indian makers are moving up to more complex products.
- Complex launches. Difficult-to-make generics face fewer competitors.
- Backward integration. Own ingredient supply supports cost and reliability.
- Wide markets. Sales in India, the United States and Europe diversify earnings.
Why Lupin Features Among These Complex Generics and Active Ingredient Stocks
Among the complex generics and active ingredient stocks on this list, Lupin is a Mumbai-headquartered global pharmaceutical company with a presence in branded generics in India, complex generics and specialty products in the United States, and active ingredients, with strength in respiratory, cardiovascular, anti-diabetic and anti-infective therapies.
Revenue rose from Rs 16,616 crore in FY22 to Rs 29,039 crore in FY26, a compound annual growth rate of 15.0%. Net profit grew from Rs 1,936 crore in FY24 to Rs 5,355 crore in FY26, which works out to a compound annual growth rate of 66.3%.
In the June 2026 quarter, revenue grew 32.5% year on year to Rs 8,407 crore, while net profit rose 16.0% to Rs 1,417 crore. The company has a return on equity of 23.8%, a debt to equity ratio of 0.29 and a market capitalisation of Rs 89,343 crore. The stock trades at a P/E of 16.1, below the industry P/E of 36.0.
Roadmap: The company is building its pipeline of complex generics, inhalation products and biosimilars, and is widening its specialty portfolio in the United States. Its large Indian branded business and a presence in over 100 markets spread revenue across regions and therapies.
What to watch: Track key launches in the United States, especially in inhalation and complex injectables, and the growth of the India branded business.
Why Dr. Reddy’s Laboratories Features Among These Complex Generics and Active Ingredient Stocks
Among the generic drug maker shares on this list, Dr. Reddy’s Laboratories is a Hyderabad-based pharmaceutical company that makes generics, active ingredients and branded products for India and global markets, with a large presence in North America and Europe.
Revenue rose from Rs 22,030 crore in FY22 to Rs 35,059 crore in FY26, a compound annual growth rate of 12.3%. Net profit grew from Rs 2,182 crore in FY22 to Rs 4,158 crore in FY26, which works out to a compound annual growth rate of 17.5%.
The company has a return on equity of 11.1%, a debt to equity ratio of 0.20 and a market capitalisation of Rs 103,667 crore. The stock trades at a P/E of 32.6, below the industry P/E of 36.0.
Roadmap: The company is widening its product pipeline with complex generics, biosimilars and consumer health, while its domestic business adds steady growth. Investment in research supports a stream of new launches.
What to watch: Monitor launches of complex generics and the progress of biosimilar programmes.
Why Granules India Features Among These Complex Generics and Active Ingredient Stocks
Among the three companies on this list, Granules India is a Hyderabad-based pharmaceutical manufacturer that makes active ingredients, intermediates and finished dosage forms, with a strong position in paracetamol, metformin and ibuprofen.
The company has a return on equity of 11.7%, a debt to equity ratio of 0.30 and a market capitalisation of Rs 22,002 crore. The stock trades at a P/E of 33.2, below the industry P/E of 36.0.
Revenue rose from Rs 3,783 crore in FY22 to Rs 5,386 crore in FY26, a compound annual growth rate of 9.2%. Net profit grew from Rs 413 crore in FY22 to Rs 595 crore in FY26, which works out to a compound annual growth rate of 9.6%. In the June 2026 quarter, revenue grew 20.6% year on year to Rs 1,479 crore, while net profit rose 59.8% to Rs 180 crore.
Roadmap: The company is shifting its mix towards finished dosages, which earn better margins than ingredients, and it supplies customers in regulated markets, especially the United States. Capacity additions and new product approvals support steady growth.
What to watch: Monitor new product approvals and the share of finished dosages in total sales.
Lupin vs Dr. Reddy’s Laboratories vs Granules India on Key Financials
The table below sets the three complex generics and active ingredient stocks side by side on revenue, profit and margin, using reported figures.
| Company | FY22 Revenue (Rs Cr) | FY26 Revenue (Rs Cr) | Revenue CAGR (FY22-FY26) | FY26 Net Profit (Rs Cr) | FY26 Net Margin |
|---|---|---|---|---|---|
| Lupin | 16,616 | 29,039 | 15.0% | 5,355 | 18.4% |
| Dr. Reddy’s Laboratories | 22,030 | 35,059 | 12.3% | 4,158 | 11.9% |
| Granules India | 3,783 | 5,386 | 9.2% | 595 | 11.0% |
Lupin posts the highest return on equity in this group at 23.8%. Dr. Reddy’s Laboratories has the largest FY26 revenue at Rs 35,059 crore, and Lupin shows the fastest revenue growth with a 15.0% compound annual rate. A useful habit with complex generics and active ingredient stocks is to check each new quarterly result against the capacity plans the company described earlier.
Key Risks to Check Before Investing in Complex Generics and Active Ingredient Stocks
Every theme carries risks that deserve a check before any decision. For these complex generics and active ingredient stocks, the main points are: Long-term generic drug maker shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.
- Pricing in export markets. Competition can weigh on generic prices.
- Regulatory checks. Plant inspections can delay launches.
- Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them.
Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.
Use the Univest Stock Screener to filter complex generics and active ingredient stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.
Final Thoughts on Complex Generics and Active Ingredient Stocks
Complex generics and active ingredient stocks reward investors who follow approvals, launches and capacity together. Lupin, Dr. Reddy’s Laboratories and Granules India each have a clear pipeline. Based on the 22 October 2026 close, Lupin trades at Rs 1,922, Dr. Reddy’s Laboratories at Rs 1,239 and Granules India at Rs 817.
Download the Univest iOS App or Univest Android App to track complex generics and active ingredient stocks, set price alerts and get research-backed stock ideas.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
What are complex generics and active ingredient stocks?
Ans. Complex generics and active ingredient stocks are listed pharmaceutical companies that make generic formulations and the ingredients behind them. Their earnings depend on approvals, launches and plant capacity. This list looks at three of them, Lupin, Dr. Reddy’s Laboratories and Granules India, using reported FY22 to FY26 financials and the 22 October 2026 closing prices.
Which complex generics and active ingredient stocks are covered in this list?
Ans. This list covers Lupin, Dr. Reddy’s Laboratories and Granules India. Based on the 22 October 2026 close, Lupin traded at Rs 1,922, Dr. Reddy’s Laboratories at Rs 1,239 and Granules India at Rs 817. Their return on equity ranges from 11.1% to 23.8%, and their revenue compound annual growth from FY22 to FY26 ranges from 9.2% to 15.0%.
Why do complex generics and active ingredient stocks have a strong future roadmap in India?
Ans. Complex generics and active ingredient stocks have a strong roadmap in India because global demand for affordable medicines keeps growing, and Indian makers are moving up to more complex products. The main drivers are as follows. Complex launches. Difficult-to-make generics face fewer competitors. Backward integration. Own ingredient supply supports cost and reliability. Wide markets. Sales in India, the United States and Europe diversify earnings. Together these factors give the companies on this list a visible path for growth over the coming years.
How has Lupin performed financially?
Ans. Revenue rose from Rs 16,616 crore in FY22 to Rs 29,039 crore in FY26, a compound annual growth rate of 15.0%. Net profit grew from Rs 1,936 crore in FY24 to Rs 5,355 crore in FY26, which works out to a compound annual growth rate of 66.3%. In the June 2026 quarter, revenue grew 32.5% year on year to Rs 8,407 crore, while net profit rose 16.0% to Rs 1,417 crore. The company has a return on equity of 23.8%, a debt to equity ratio of 0.29 and a market capitalisation of Rs 89,343 crore. The stock trades at a P/E of 16.1, below the industry P/E of 36.0. Looking ahead, the company is building its pipeline of complex generics, inhalation products and biosimilars, and is widening its specialty portfolio in the United States. Its large Indian branded business and a presence in over 100 markets spread revenue across regions and therapies.
How has Dr. Reddy’s Laboratories performed financially?
Ans. Revenue rose from Rs 22,030 crore in FY22 to Rs 35,059 crore in FY26, a compound annual growth rate of 12.3%. Net profit grew from Rs 2,182 crore in FY22 to Rs 4,158 crore in FY26, which works out to a compound annual growth rate of 17.5%. The company has a return on equity of 11.1%, a debt to equity ratio of 0.20 and a market capitalisation of Rs 103,667 crore. The stock trades at a P/E of 32.6, below the industry P/E of 36.0. Looking ahead, the company is widening its product pipeline with complex generics, biosimilars and consumer health, while its domestic business adds steady growth. Investment in research supports a stream of new launches.
How has Granules India performed financially?
Ans. Revenue rose from Rs 3,783 crore in FY22 to Rs 5,386 crore in FY26, a compound annual growth rate of 9.2%. Net profit grew from Rs 413 crore in FY22 to Rs 595 crore in FY26, which works out to a compound annual growth rate of 9.6%. In the June 2026 quarter, revenue grew 20.6% year on year to Rs 1,479 crore, while net profit rose 59.8% to Rs 180 crore. The company has a return on equity of 11.7%, a debt to equity ratio of 0.30 and a market capitalisation of Rs 22,002 crore. The stock trades at a P/E of 33.2, below the industry P/E of 36.0. Looking ahead, the company is shifting its mix towards finished dosages, which earn better margins than ingredients, and it supplies customers in regulated markets, especially the United States. Capacity additions and new product approvals support steady growth.
What risks should investors check before buying complex generics and active ingredient stocks?
Ans. Investors should check a few risks before buying complex generics and active ingredient stocks. Pricing in export markets. Competition can weigh on generic prices. Regulatory checks. Plant inspections can delay launches. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.
Is this list of complex generics and active ingredient stocks investment advice?
Ans. No. This article is educational and uses publicly available data as of the 22 October 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.
